Additionally, savolitinib is being studied in patients with MET-driven resistance to EGFR TKIs in combination with osimertinib (SAVANNAH, NCT03778229; SAFFRON, NCT05261399; ORCHARD, NCT03944772; NCT03944771; SACHI, NCT05015608) and further in EGFR-mutant NSCLC patients with de novo MET positive alterations as first-line setting (FLOWERS, NCT05163249; SANOVO, NCT05009836) (www.clinicaltrial.gov, accessed on 14 May 2023). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.